GB261

About Ab Studio

Ab Studio is a private, platform-based biotech leveraging computational design to create next-generation multi-specific antibodies. Its core strength lies in a suite of proprietary technology platforms (e.g., FETA, CATA) aimed at enhancing efficacy, safety, and manufacturability. The company has advanced multiple candidates into clinical trials via partners, most notably the bispecific GB261 and trispecific GB263T, and engages in service projects and research collaborations, indicating a diversified operational approach. While pre-revenue from product sales, its model generates value through partnerships and licensing deals.

Therapeutic Areas